Thrombosis Research

Papers
(The TQCC of Thrombosis Research is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
ArticleCitations
Incidence of thrombotic complications in critically ill ICU patients with COVID-193251
Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy1549
Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis1208
The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management430
Severe COVID-19 infection associated with endothelial activation338
Thrombosis risk associated with COVID-19 infection. A scoping review285
Incidence of asymptomatic deep vein thrombosis in patients with COVID-19 pneumonia and elevated D-dimer levels276
Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID)190
The clinical implication of dynamic neutrophil to lymphocyte ratio and D-dimer in COVID-19: A retrospective study in Suzhou China180
Venous thromboembolism in patients with COVID-19: Systematic review and meta-analysis170
D-dimer level is associated with the severity of COVID-19144
Pulmonary embolism in patients with COVID-19: Time to change the paradigm of computed tomography143
Clinical and computed tomography characteristics of COVID-19 associated acute pulmonary embolism: A different phenotype of thrombotic disease?138
Thrombotic complications of patients admitted to intensive care with COVID-19 at a teaching hospital in the United Kingdom136
Mechanisms involved in the development of thrombocytopenia in patients with COVID-19121
Severe arterial thrombosis associated with Covid-19 infection113
Is COVID-19 associated thrombosis caused by overactivation of the complement cascade? A literature review104
Estrogen and thrombosis: A bench to bedside review97
Antiphospholipid antibodies are not elevated in patients with severe COVID-19 pneumonia and venous thromboembolism92
Anticoagulation and bleeding risk in patients with COVID-1992
Image-proven thromboembolism in patients with severe COVID-19 in a tertiary critical care unit in the United Kingdom91
Admission D-dimer levels, D-dimer trends, and outcomes in COVID-1979
Incidence of thrombotic complications and overall survival in hospitalized patients with COVID-19 in the second and first wave76
Pulmonary embolism in hospitalised patients with COVID-1973
Spontaneous HIT syndrome: Knee replacement, infection, and parallels with vaccine-induced immune thrombotic thrombocytopenia73
Pulmonary embolism in COVID-19 patients: prevalence, predictors and clinical outcome72
The role of Neutrophil Extracellular Traps in Covid-19: Only an hypothesis or a potential new field of research?72
Mechanisms of thrombosis and cardiovascular complications in COVID-1971
COVID-19 and cardiovascular consequences: Is the endothelial dysfunction the hardest challenge?69
Incidence of venous and arterial thromboembolic complications in COVID-19: A systematic review and meta-analysis69
ADAMTS13 activity, von Willebrand factor, factor VIII and D-dimers in COVID-19 inpatients65
Are antiphospholipid antibodies associated with thrombotic complications in critically ill COVID-19 patients?64
A relative ADAMTS13 deficiency supports the presence of a secondary microangiopathy in COVID 1955
Venous thromboembolism in non-critically ill patients with COVID-19 infection55
Venous and arterial thromboembolic events with immune checkpoint inhibitors: A systematic review55
COVID-19 and thrombotic microangiopathies52
Biomarkers for the prediction of venous thromboembolism in critically ill COVID-19 patients51
Hypotheses behind the very rare cases of thrombosis with thrombocytopenia syndrome after SARS-CoV-2 vaccination48
Incidence of symptomatic venous thromboembolism following hospitalization for coronavirus disease 2019: Prospective results from a multi-center study47
Sustained inflammation, coagulation activation and elevated endothelin-1 levels without macrovascular dysfunction at 3 months after COVID-1946
Pulmonary embolism in a young pregnant woman with COVID-1944
Drug-drug interactions with direct oral anticoagulants associated with adverse events in the real world: A systematic review44
Prevalence and characteristics of pulmonary embolism in 1042 COVID-19 patients with respiratory symptoms: A nested case-control study44
In vitro hemocompatibility testing of medical devices44
D-dimer cut-off points and risk of venous thromboembolism in adult hospitalized patients with COVID-1944
Genetically predicted obesity and risk of deep vein thrombosis43
Measuring functional limitations after venous thromboembolism: Optimization of the Post-VTE Functional Status (PVFS) Scale43
Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the INSPIRATION/INSPIRATION-S studies43
Covid-19 associated autoimmune thrombotic thrombocytopenic purpura: Report of a case42
Incidence and impact of disseminated intravascular coagulation in COVID-19 a systematic review and meta-analysis41
The gut microbiome and thromboembolism41
Thrombotic antiphospholipid syndrome: A practical guide to diagnosis and management40
Incidence and mortality due to thromboembolic events during the COVID-19 pandemic: Multi-sourced population-based health records cohort study38
Recombinant ADAMTS13 reduces abnormally up-regulated von Willebrand factor in plasma from patients with severe COVID-1938
The effect of anticoagulation on clinical outcomes in novel Coronavirus (COVID-19) pneumonia in a U.S. cohort37
Venous thrombotic events in patients treated with immune checkpoint inhibitors for non-small cell lung cancer: A retrospective multicentric cohort study37
Venous thromboembolism and bleeding in critically ill COVID-19 patients treated with higher than standard low molecular weight heparin doses and aspirin: A call to action36
Intensity of anticoagulation and survival in patients hospitalized with COVID-19 pneumonia36
Pulmonary infarction in acute pulmonary embolism36
Cerebral venous thrombosis and thrombocytopenia post-COVID-19 vaccination36
Prothrombotic disturbances of hemostasis of patients with severe COVID-19: A prospective longitudinal observational study35
COVID-19 versus HIT hypercoagulability35
Incidence of venous thromboembolic events in COVID-19 patients after hospital discharge: A systematic review and meta-analysis35
Impact of implementation of an individualised thromboprophylaxis protocol in critically ill ICU patients with COVID-19: A longitudinal controlled before-after study34
Lemierre syndrome: Current evidence and rationale of the Bacteria-Associated Thrombosis, Thrombophlebitis and LEmierre syndrome (BATTLE) registry34
Targeting raised von Willebrand factor levels and macrophage activation in severe COVID-19: Consider low volume plasma exchange and low dose steroid32
Higher procoagulatory potential but lower DIC score in COVID-19 ARDS patients compared to non-COVID-19 ARDS patients31
Portal vein thrombosis in a patient with COVID-1931
Current imaging modalities for diagnosing cerebral vein thrombosis – A critical review31
COVID-19 associated coagulopathy: Thrombosis, hemorrhage and mortality rates with an escalated-dose thromboprophylaxis strategy30
Intestinal microbiota dysbiosis play a role in pathogenesis of patients with primary immune thrombocytopenia29
COVID-19 and thrombosis: The role of hemodynamics29
Arterial and venous thromboembolic disease in a patient with COVID-19: A case report29
Thrombotic risk in children with COVID-19 infection: A systematic review of the literature29
Relationship between body mass index, risk of venous thromboembolism and pulmonary embolism: A systematic review and dose-response meta-analysis of cohort studies among four million participants29
Pulmonary embolism: A complication of COVID 19 infection28
Systemic thrombosis in a large cohort of COVID-19 patients despite thromboprophylaxis: A retrospective study28
Endothelial function improvement in patients with familial hypercholesterolemia receiving PCSK-9 inhibitors on top of maximally tolerated lipid lowering therapy28
Incidence of thrombotic outcomes for patients hospitalized and discharged after COVID-19 infection27
Advances in the management of coagulopathy in acute promyelocytic leukemia27
Prediction models for recurrence and bleeding in patients with venous thromboembolism: A systematic review and critical appraisal26
Risk prediction for cancer-associated thrombosis in ambulatory patients with cancer: past, present and future26
ADAMTS 13 deficiency is associated with abnormal distribution of von Willebrand factor multimers in patients with COVID-1926
Is bivalirudin an alternative anticoagulant for extracorporeal membrane oxygenation (ECMO) patients? A systematic review and meta-analysis25
Catheter-directed thrombolysis in COVID-19 pneumonia with acute PE: Thinking beyond the guidelines25
Apixaban and rivaroxaban anti-Xa level utilization and associated bleeding events within an academic health system25
A comprehensive assessment of the coagulation profile in critically ill COVID-19 patients25
Translational insight into prothrombotic state and hypercoagulation in nonalcoholic fatty liver disease25
The antithrombotic effect of caffeic acid is associated with a cAMP-dependent pathway and clot retraction in human platelets25
Efficacy and safety of a 12-week outpatient pulmonary rehabilitation program in Post-PE Syndrome24
Novel contributions of neutrophils in the pathogenesis of abdominal aortic aneurysm, the role of neutrophil extracellular traps: A systematic review24
Management of venous thromboembolism in pregnancy24
Clinical practice guidelines for the treatment and prevention of cancer-associated thrombosis24
Timing of venous thromboembolism diagnosis in hospitalized and non-hospitalized patients with COVID-1924
Anti Xa activity after high dose LMWH thrombosis prophylaxis in covid 19 patients at the intensive care unit23
Venous thromboembolic events in the setting of extracorporeal membrane oxygenation support in adults: A systematic review23
Bacterial outer membrane vesicles induce disseminated intravascular coagulation through the caspase-11-gasdermin D pathway23
The use of prophylaxis in the treatment of rare bleeding disorders23
The significance of disseminated intravascular coagulation on multiple organ dysfunction during the early stage of acute respiratory distress syndrome23
Blocking podoplanin inhibits platelet activation and decreases cancer-associated venous thrombosis23
Links between thrombosis and inflammation in traumatic brain injury23
COVID-19 and thrombotic complications: Pulmonary thrombosis rather than embolism?22
Arterial and venous thrombosis: What's the link? A narrative review22
Antiphospholipid syndrome and antiphospholipid antibody profile in patients with retinal vein occlusion22
A perioperative bivalirudin anticoagulation protocol for neonates with congenital diaphragmatic hernia on extracorporeal membrane oxygenation22
Venous thromboembolism and coronavirus disease 2019 in an ambulatory care setting - A report of 4 cases22
Absence of hypercoagulability after nCoV-19 vaccination: An observational pilot study22
Comparative effectiveness of oral anticoagulants in venous thromboembolism: GARFIELD-VTE22
The domino effect triggered by the tethered ligand of the protease activated receptors22
A perfect storm: Root cause analysis of supra-therapeutic anticoagulation with vitamin K antagonists during the COVID-19 pandemic21
The increased risk of bleeding due to drug-drug interactions in patients administered direct oral anticoagulants21
Deep venous thrombosis in a non-critically ill patient with novel COVID-19 infection21
Thrombotic thrombocytopenic purpura (TTP) after COVID-19 vaccination: A systematic review of reported cases21
ROTEM diagnostic capacity for measuring fibrinolysis in neonatal sepsis21
Heavy menstrual bleeding in women on oral anticoagulants21
The thrombin–inflammation axis in cancer progression21
Age-adjusted D-dimer cut-off levels to rule out venous thromboembolism in COVID-19 patients21
Anti-Xa monitoring improves low-molecular-weight heparin effectiveness in patients with SARS-CoV-2 infection21
Pulmonary embolism and deep vein thrombosis: Similar but different20
A single center retrospective cohort study evaluating use of direct oral anticoagulants (DOACs) in morbidly obese veteran population20
Predictive value of D-dimer testing for the diagnosis of venous thrombosis in unusual locations: A systematic review20
Recombinant human DNase I for the treatment of cancer-associated thrombosis: A pre-clinical study20
Rotational thromboelastometry to assess hypercoagulability in COVID-19 patients20
Role of upfront CT pulmonary angiography at admission in COVID-19 patients20
Platelet-leukocyte crosstalk in COVID-19: How might the reciprocal links between thrombotic events and inflammatory state affect treatment strategies and disease prognosis?19
Diverse thrombus composition in thrombectomy stroke patients with longer time to recanalization19
Determinants of plasma fibrin clot lysis measured using three different assays in healthy subjects19
COVID-19 and hypercoagulability in the outpatient setting19
Testosterone replacement therapy and the risk of venous thromboembolism: A systematic review and meta-analysis of randomized controlled trials19
Unusual simultaneous cerebral infarcts in multiple arterial territories in a COVID-19 patient19
Using oral anticoagulants among chronic kidney disease patients to prevent recurrent venous thromboembolism: A systematic review and meta-analysis19
Four cases of acquired hemophilia A following immunization with mRNA BNT162b2 SARS-CoV-2 vaccine19
Deaths related to pulmonary embolism and cardiovascular events before and during the 2020 COVID-19 pandemic: An epidemiological analysis of data from an Italian high-risk area18
Tissue factor in COVID-19-associated coagulopathy18
Interference of DOAC stop and DOAC remove in the thrombin generation assay and coagulation assays18
Management of high-risk pulmonary embolism in pregnancy18
Utility of D-dimers and intermediate-dose prophylaxis for venous thromboembolism in critically ill patients with COVID-1918
Three-month follow-up of pulmonary embolism in patients with COVID-1918
Risk of post-thrombotic syndrome after deep vein thrombosis treated with rivaroxaban versus vitamin-K antagonists: A systematic review and meta-analysis18
An overview of thrombotic complications of old and new anticancer drugs17
The pathogenesis of thromboembolic disease in covid-19 patients: Could be a catastrophic antiphospholipid syndrome?17
Prevalence of aPhosphatidylserine/prothrombin antibodies and association with antiphospholipid antibody profiles in patients with antiphospholipid syndrome: A systematic review and meta-analysis17
Oral contraceptives and hormone replacement therapy: How strong a risk factor for venous thromboembolism?17
Twice- or Once-Daily Dosing of Direct Oral Anticoagulants, a systematic review and meta-analysis17
Direct-acting oral anticoagulants use prior to COVID-19 diagnosis and associations with 30-day clinical outcomes17
Time from suspected thrombotic thrombocytopenic purpura to initiation of plasma exchange and impact on survival: A 10-year provincial retrospective cohort study17
Extended half-life recombinant products in haemophilia clinical practice – Expectations, opportunities and challenges17
D-dimer as a stand-alone test to rule out deep vein thrombosis16
Direct oral anticoagulant versus low-molecular-weight heparin for treatment of venous thromboembolism in cancer patients: An updated meta-analysis of randomized controlled trials16
The impact of hydroxychloroquine on obstetric outcomes in refractory obstetric antiphospholipid syndrome16
COVID-19 associated pulmonary thrombosis16
Rise of levels of von Willebrand factor and factor VIII with age: Role of genetic and acquired risk factors16
How we make an accurate diagnosis of von Willebrand disease16
Incidence of thromboembolic events following administration of four-factor prothrombin complex concentrate (4F-PCC) for oral anticoagulation reversal16
Administrative codes inaccurately identify recurrent venous thromboembolism: The CVRN VTE study16
Long-term follow-up after successful treatment of vaccine-induced prothrombotic immune thrombocytopenia16
Direct oral anticoagulants or low-molecular-weight heparins for venous thromboembolism in patients with brain tumors16
Extracellular vesicles in atrial fibrillation and stroke16
Venous thromboembolism incidence and risk factors in non-small cell lung cancer patients receiving first-line systemic therapy16
Extended thromboprophylaxis following major abdominal/pelvic cancer-related surgery: A systematic review and meta-analysis of the literature16
Low molecular weight heparin and 28-day mortality among patients with coronavirus disease 2019: A cohort study in the early epidemic era16
High plasma levels of soluble P-Selectin and Factor VIII predict venous thromboembolism in non-small cell lung cancer patients: The Thrombo-Nsclc risk score16
Preoperative and intraoperative predictors of deep venous thrombosis in adult patients undergoing craniotomy for brain tumors: A Chinese single-center, retrospective study16
Association between neutrophil extracellular traps (NETs) and thrombosis in antiphospholipid syndrome15
Reduced intracellular antioxidant capacity in platelets contributes to primary immune thrombocytopenia via ROS-NLRP3-caspase-1 pathway15
Deep vein thrombosis in SARS-CoV-2 pneumonia-affected patients within standard care units: Exploring a submerged portion of the iceberg15
Coagulation signaling and cancer immunotherapy15
Risk of symptomatic venous thromboembolism in mild and moderate COVID-19: A comparison of two prospective European cohorts15
Asymptomatic deep vein thrombosis in critically ill COVID-19 patients despite therapeutic levels of anti-Xa activity15
Translating the success of prophylaxis in haemophilia to von Willebrand disease15
Low admission protein C levels are a risk factor for disease worsening and mortality in hospitalized patients with COVID-1915
Venous thromboembolism following 672,495 primary total shoulder and elbow replacements: Meta-analyses of incidence, temporal trends and potential risk factors15
Suggestions for global coagulation assays for the assessment of COVID-19 associated hypercoagulability15
A nomogram model to predict the venous thromboembolism risk after surgery in patients with gynecological tumors15
Development and prospective validation of a novel risk score for predicting the risk of lower extremity deep vein thrombosis among multiple trauma patients15
Apixaban and rivaroxaban in obese patients treated for venous thromboembolism: Drug levels and clinical outcomes15
How I treat von Willebrand disease15
Genetic and epigenetic regulation of cancer coagulome – lessons from heterogeneity of cancer cell populations15
Hemostatic biomarkers in occult cancer and cancer risk prediction15
Immature platelets: a review of the available evidence14
Patients experience of living with cancer associated thrombosis in France (Le PELICAN)14
Markers of NET formation and stroke risk in patients with atrial fibrillation: association with a prothrombotic state14
Selatogrel, a reversible P2Y12 receptor antagonist, has reduced off-target interference with haemostatic factors in a mouse thrombosis model14
Where do we stand with antithrombotic prophylaxis in patients with COVID-19?14
Thrombosis in hematological malignancies: mechanisms and implications14
Effects of platelet and phospholipids on clot formation activated by a small amount of tissue factor14
The role of P-selectin in cancer-associated thrombosis and beyond14
Lifestyle factors and venous thromboembolism in two cohort studies14
Predictors of residual pulmonary vascular obstruction after pulmonary embolism: Results from a prospective cohort study14
Venous thromboembolism in Asia and worldwide: Emerging insights from GARFIELD-VTE14
The hazard of fondaparinux in non-critically ill patients with COVID-19: Retrospective controlled study versus enoxaparin14
Validation of the PLASMIC score for predicting ADAMTS13 activity <10% in patients with suspected thrombotic thrombocytopenic purpura in Alberta, Canada14
Real-time detection and differentiation of direct oral anticoagulants (rivaroxaban and dabigatran) using modified thromboelastometric reagents14
Pharmacokinetics for haemophilia treaters: Meaning of PK parameters, interpretation pitfalls, and use in the clinic14
COVID-19 risk perceptions, worries and preventive behaviors in patients with previous pulmonary embolism14
The prevalence of pulmonary embolism in patients with COVID-19 and respiratory decline: A three-setting comparison14
Risk of VTE associated with PORTs and PICCs in cancer patients: A systematic review and meta-analysis14
Prediction of hypofibrinogenemia and thrombocytopenia at the point of care with the Quantra® QPlus® System13
Incidence and prevalence of venous thromboembolism in Norway 2010–201713
COVID-19 adenovirus vaccine triggers antibodies against PF4 complexes to activate complement and platelets13
Longitudinal multiparametric characterization of platelet dysfunction in COVID-19: Effects of disease severity, anticoagulation therapy and inflammatory status13
Current estimates of the incidence of acute venous thromboembolic disease in Canada: A meta-analysis13
Extensive pulmonary perfusion defects compatible with microthrombosis and thromboembolic disease in severe Covid-19 pneumonia13
Short-term exposure to PM2.5 and risk of venous thromboembolism: A case-crossover study13
Coagulation parameters and venous thromboembolism in patients with and without COVID-19 admitted to the Emergency Department for acute respiratory insufficiency13
Nephrotic syndrome disease activity is proportional to its associated hypercoagulopathy13
Knockdown of liver-derived factor XII by GalNAc-siRNA ALN-F12 prevents thrombosis in mice without impacting hemostatic function13
Prothrombotic abnormalities in patients with multiple myeloma and monoclonal gammopathy of undetermined significance13
The neutrophil-lymphocyte ratio and platelet-lymphocyte ratio predict left ventricular thrombus resolution in acute myocardial infarction without percutaneous coronary intervention13
Overview of risk assessment models for venous thromboembolism in ambulatory patients with cancer13
Anticoagulation in COVID-19 patients – An updated systematic review and meta-analysis13
Increased levels of platelet-derived microparticles in pulmonary hypertension13
COVID-19 coagulopathy and thrombosis: Analysis of hospital protocols in response to the rapidly evolving pandemic13
Influence of sex on development of thrombosis in patients with COVID-19: From the CLOT-COVID study13
Developing and validating natural language processing algorithms for radiology reports compared to ICD-10 codes for identifying venous thromboembolism in hospitalized medical patients13
ADAMTS13 activity, high VWF and FVIII levels in the pathogenesis of deep vein thrombosis13
Frequency and incidence of arterial events in patients with venous thromboembolism compared to the general population: A systematic review and meta-analysis of cohort studies12
Letter to the Editors-in-Chief in response to the article of Abou-Ismail, et al. entitled “Estrogen and thrombosis: A bench to bedside review” (Thrombosis Research 192 (2020) 40–51)12
Management and outcomes of cancer patients with venous thromboembolism presenting with thrombocytopenia12
Occurrence of pulmonary embolism in a patient with mild clinical expression of COVID-1912
Pharmacokinetics of enoxaparin in COVID-19 critically ill patients12
Neutrophil extracellular traps and cancer-associated thrombosis12
Persistent circulating platelet and endothelial derived microparticle signature may explain on-going pro-thrombogenicity after acute coronary syndrome12
Association between Covid-19 and Pulmonary Embolism (AC-19-PE study)12
Biomarker association with cardiovascular disease and mortality – The role of fibrinogen. A report from the NHANES study12
Splanchnic vein thrombosis associated with myeloproliferative neoplasms12
Venous and arterial thromboembolism in patients with cancer treated with targeted anti-cancer therapies12
Coagulation factors XI and XII as possible targets for anticoagulant therapy12
Real-world experience with reversal of dabigatran by idarucizumab12
A comparison of natural language processing to ICD-10 codes for identification and characterization of pulmonary embolism12
NLRP3 inflammasome contributes to endotoxin-induced coagulation12
Efficacy and safety of apixaban for primary prevention in gastrointestinal cancers: A post-hoc analysis of the AVERT trial12
“Whole life changed” - Experiences of how symptoms derived from acute pulmonary embolism affects life. A qualitative interview study12
Cancer-associated thrombosis in pediatric patients12
Pulmonary embolism in coronavirus disease-19 (COVID-19) and use of compression ultrasonography in its optimal management12
Comparison of clinical outcomes using activated partial thromboplastin time versus antifactor-Xa for monitoring therapeutic unfractionated heparin: A systematic review and meta-analysis12
Patient-reported outcomes associated with changing to rivaroxaban for the treatment of cancer-associated venous thromboembolism – The COSIMO study12
Cancer-associated non-bacterial thrombotic endocarditis12
Brain-derived extracellular vesicles mediated coagulopathy, inflammation and apoptosis after sepsis12
Pulmonary embolism: Age specific temporal trends in incidence and mortality in Denmark 1999–201812
Multiparameter microfluidics assay of thrombus formation reveals increased sensitivity to contraction and antiplatelet agents at physiological temperature11
The incidence of thrombotic events with idarucizumab and andexanet alfa: A systematic review and meta-analysis11
A new hybrid immunocapture bioassay with improved reproducibility to measure tissue factor-dependent procoagulant activity of microvesicles from body fluids11
One-year incidence of venous thromboembolism, bleeding, and death in patients with solid tumors newly initiating cancer treatment: Results from the Cancer-VTE Registry11
Adherence to and persistence with direct oral anticoagulant therapy among patients with new onset venous thromboembolism receiving extended anticoagulant therapy and followed by a centralized anticoag11
Impact of a commercially available DOAC absorbent on two integrated procedures for lupus anticoagulant detection11
Tissue plasminogen activator for the treatment of adults with critical COVID-19: A pilot randomized clinical trial11
Erythrocytosis and thromboembolic events in transgender individuals receiving gender-affirming testosterone11
Upregulation of mechanosensitive channel Piezo1 involved in high shear stress-induced pulmonary hypertension11
Antisense oligonucleotides and nucleic acids generate hypersensitive platelets11
0.027230024337769